Article Text

PDF
THU0422 Psychometric Properties of the Brief Fatigue Inventory-Short Form in Systemic Lupus Erythematosus
  1. S. Al Sawah,
  2. A.N. Naegeli
  1. Eli Lilly and Company, Indianapolis, United States

Abstract

Background A 12-week prospective, observational study was conducted to evaluate the psychometric properties of the Brief Fatigue Inventory-Short Form (BFI-SF)1 and determine its appropriate use for the measurement of fatigue in systemic lupus erythematosus (SLE) clinical trials.

Objectives The aim of this study was to validate the performance of BFI-SF in a sample of patients with moderate-to-severe SLE.

Methods Participants ≥18 years, who self-reported a physician diagnosis of SLE (confirmed by medical record review) and active SLE demonstrated by a Systemic Lupus Activity Questionnaire (SLAQ) score of ≥11 (0-44 scale), were recruited using a free electronic medication monitoring service. All participants completed the BFI-SF, Multidimensional Assessment of Fatigue (MAF), and Medical Outcome Study 36-Item Short Form Health Survey (SF-36) electronically at baseline, week 2, and week 12. Score distributions, internal consistency, test-retest reliability, and construct validity were evaluated.

Results A total of 122 participants were included in the study. The mean age was 45.7 years, 95.9% were female, and 68.9% were non-Hispanic white. Cronbach's alpha were >0.9 for all BFI-SF items. Test-retest reliability of the BFI-SF showed a stable intraclass correlation for item #7 (ICC 0.76), and BFI domain scores had higher correlations (around 0.5) than most items (around 0.3-0.4). Construct validity was measured by strength of the correlations of the BFI-SF severity domains and global scores, and were moderately positively correlated to the SLAQ score (r>0.4). The domain and global scores were moderately negatively correlated to the SF-36 Vitality and Physical Function domains and SF-36 Physical Component scores (all r<-0.3). The BFI-SF item #3 for worst fatigue was highly positively correlated to the MAF (r=0.6). Patients with less severe fatigue (MAF≤36) scored lower than patients with more severe fatigue (MAF>36) on all domains of the BFI-SF (total score, 4.66±1.55 vs. 6.80±1.13; p<0.0001).

Conclusions Assessment of fatigue severity and the impact of fatigue on daily functioning as measured by the BFI-SF demonstrated validity and reliability in a sample of patients with SLE and may be used as a patient-reported outcome tool in clinical trials.

References

  1. Mendoza TR, et al. Cancer 1999;85:1186-96

Acknowledgements This research was funded by Eli Lilly and Company, Indianapolis, IN.

Disclosure of Interest : S. Al Sawah Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, A. Naegeli Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company

DOI 10.1136/annrheumdis-2014-eular.2055

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.